

References

1. Waters JH, Ness PM. Patient blood management: a growing challenge and opportunity. *Transfusion* 2011; 51: 902-903.
2. Markowitz MA, Waters JH, Ness PM. Patient blood management: a primary theme in transfusion medicine. *Transfusion* 2014; 54: 2587.
3. Callum JL, Waters JH, Shah BH, et al. The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine. *Transfusion* 2014; 54: 2344-2352.
4. Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations from the 2018 Frankfurt Consensus Conference. *JAMA*. 2019; 321: 983-997.
5. Ontario Regional Blood Coordinating Network. <https://transfusionontario.org/en/>
6. Canadian Society for Transfusion Medicine. Ten Things Physicians and Patients Should Question. <https://www.transfusion.ca/Education/Choosing-Wisely/CSTM-Choosing-Wisely-List>
Accessioned 24/2/2022.
7. Leahy MF, Hofman A, Towler S, et al. Improved outcomes and reduced costs with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. *Transfusion* 2017; 57: 1347-1358.
8. Lin Y, Cserti-Gazdewicz C, Lieberman L, et al. Improving transfusion practice with guidelines and prospective auditing by medical laboratory technologists. *Transfusion* 2016; 56: 2903-2905.
9. Kron AT, Collins A, Cserti-Gazdewicz C, et al. A prospective multi-faceted interventional

study of blood bank technologist screening of red blood cell transfusion orders. *Transfusion* 2021; 61: 410-422.

10. Tinmouth A, Thompson T, Arnold DM, et al. Utilization of frozen plasma in Ontario: a province-wide audit reveals a high rate of inappropriate transfusion. *Transfusion* 2013; 53: 2222-2229.
11. Tavares M, DiQuattro P, Nolette N, et al. Reduction in plasma transfusion after enforcement of transfusion guidelines. *Transfusion* 2011; 51: 754-761.
12. Nixon CP, Tavares MF, Sweeney JD. How do we reduce plasma transfusion in Rhode Island. *Transfusion* 2017; 57: 1863-1873.
13. Hill-Strathy MJ, Pinkerton PH, Thompson TA, et al. Evaluating the appropriateness of platelet transfusions compared with evidence-based guidelines: an audit of platelet transfusions at 57 hospitals. *Transfusion* 2021; 61: 57-71.
14. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. *Ann Intern Med* 2015; 162: 205-213.
15. Nahirniak S, Slichter SJ, Tanael S, et al. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. *Transfus Med Rev* 2015; 29: 3-13.
16. Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update. *J Clin Oncol*. 2018; 36: 283-299.
17. Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-Part II: Recommendations: Endorsed

by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. *J Vasc Interv Radiol*. 2019; 30: 1168-1184.e1.

18. Callum JL, Yeh CH, Petrosniak A, et al. A regional massive hemorrhage protocol developed through a modified Delphi technique. *CMAJ Open*. 2019; 7: E546-E561.
19. Canadian Blood Services. Circular of Information. www.blood.ca/en/hospital-services/products/component-types/circular-information Accessed 24/2/2022.
20. Gammon HM, Waters JH, Watt A, et al. Developing performance measures for Patient Blood Management. *Transfusion* 2011; 51: 2500-2509.
21. Expert Working Group. Guidelines for red blood cell and plasma transfusion for adults and children. *CMAJ* 1997; 156 (Suppl 11): S1-S24.
22. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB. Red blood cell transfusion thresholds and storage. *JAMA* 2016; 316: 2025-2035.
23. Kaufman RM, Dinh A, Cohn CS, et al. BEST Collaborative. Electronic patient identification for sample labeling reduces wrong blood in tube errors. *Transfusion* 2019; 59: 972-980.
24. de Gast-Bakker DH, de Wilde RBP, Hazekamp MG, et al. Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized control trial. *Intensive Care Med* 2013; 39: 2011-2019.
25. Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red blood cell transfusions. *Br J Haematol* 2001; 113: 24-31.
26. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper

gastrointestinal bleeding. *NEJM* 2013; 368: 11-21.

27. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: The REALITY Randomized Clinical Trial. *JAMA* 2021; 325: 552-560.
28. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *NEJM* 1999; 340: 409-417.
29. Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. *NEJM* 2017; 377: 2133-2144.
30. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. *NEJM* 2007; 357: 965-976.
31. Litton E, Latham P, Inman J, et al. Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis. *Intensive Care Med* 2019; 45:1190–1199.
32. Lasocki S, Asfar P, Jaber S, et al. Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. *Crit Care* 2021; 25: 62.
33. Litton E, Baker S, Erber WN, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial: A randomized trial of IV iron in critical illness. *Intensive Care Med* 2016; 42: 1715-1722.
34. Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. *NEJM* 2007; 356: 1609-1619.

35. New HV, Berryman J, Bolton-Maggs PH. Guidelines on transfusion for fetuses, neonates and older children. *Br J Haematol* 2016; 175: 784-828.
36. Lin JC, Strauss RG, Kulhavy JC, et al. Phlebotomy overdraw in the neonatal intensive care nursery. *Pediatrics* 2000; 106: E19.
37. Kirpalani H, Bell EF, Hintz SR, et al. Higher or lower hemoglobin transfusion thresholds for preterm infants. *NEJM* 2020; 383: 2639-2651.
38. Chapman J, Marfurt S, Reid J. Effectiveness of delayed cord clamping in reducing postdelivery complications in preterm infants: A Systematic Review. *J Perinat Neonatal Nurs.* 2016; 30: 372-378.
39. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. *NEJM* 2011; 365: 2453-2462.
40. Prick B, Jansen A, Steegers E, et al. Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. *BJOG* 2014; 121: 1005-1014.
41. Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. *Leuk Res* 2008; 32: 1338-1353.
42. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. *Int J Hematol* 2008; 88: 24-29.
43. Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. *Br J Haematol* 2022; 196: 336-350.
44. Guidelines for the clinical care of patients with thalassemia in Canada.
http://www.thalassemia.ca/wp-content/uploads/Thalassemia-Guidelines_LR.pdf

Accessioned 24/2/2022.

45. Leitch HA, Buckstein R, Zhu N, et al. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. *Leuk Res.* 2018; 74: 21-41.
46. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. *NEJM* 2010; 362: 600-613.
47. Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. *Blood* 2015; 125: 1470-1476.
48. Mattson MK, Groves C, Smith MM, et al. Platelet transfusion: The effects of a fluid warmer on platelet function. *Transfusion.* 2021; 61: 52-56.
49. Cid J, Lozano M, Zinman A, et al. Low frequency of anti-D alloimmunization after D-incompatible platelet transfusions (ADAPT) study. *Br J Haematol* 2015; 168: 598–603.
50. Roseff SD, Luban NLC, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. *Transfusion* 2002; 42: 1398-1413.
51. Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. *Br J Haematol* 2004; 124: 433-453.
52. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. *NEJM* 1997; 337: 1861-1870.
53. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guideline of the American Society of Clinical Oncology. *J Clin Oncol*

2001; 19: 1519-1538.

54. Saris A, Pavenski K. Human leucocyte antigen alloimmunization and alloimmune platelet refractoriness. *Transfus Med Rev* 2020; 34: 250-257.
55. Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. *Br J Haematol.* 2017; 176: 365-394. Erratum *Br J Haematol.* 2017; 177: 157.
56. George JN, Woolf SH, Raskob JE, et al. Idiopathic thrombocytopenia purpura; a practice guideline developed by explicit methods for the American Society of Hematology. *Blood* 1996; 88: 3-40.
57. Platelet counts and Obstetric analgesia and anaesthesia https://www.oaa-anaes.ac.uk/assets/managed/editor/file/guidelines/coagulation/platelet_counts_and_oa_lyons_hunt.pdf Accessed 24/2/2022.
58. Estcourt LJ. Thrombocytopenia in surgery and neuraxial anesthesia. *Semin Hemost Thromb* 2020; 46: 245-255.
59. Etchill EW, Myers SP, Raval JS, et al. Platelet transfusion in critical care and surgery: Evidence-based review of contemporary practice and future directions. *Shock* 2017; 47: 537-549.
60. Baharoglu MI, Cordonnier C, Salman RA, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial. *Lancet* 2016; 387: 2605-2613.
61. Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. *NEJM* 2019; 380: 242-251.
62. Estcourt LJ. Platelet transfusion threshold in premature infants (PlaNet-2 Trial). *Transfus*

Med 2019; 29: 20-22.

63. Lieberman L, Greinacher A, Murphy MF, et al. International Collaboration for Transfusion Medicine Guidelines (ICTMG). Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. *Br J Haematol* 2019; 185: 549-562.
64. Green L, Bolton-Maggs P, Beattie C, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. *Br J Haematol*. 2018; 181: 54-67. Addendum in: *Br J Haematol*. 2018; 181: 864.
65. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. *Crit Care* 2019; 23: 98.
66. O'Shaughnessy DF, Atterbury C, Bolton-Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. *Br J Haematol* 2004; 126: 11-28.
67. Roberts HR, Monroe III DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways. In *Williams Hematology*, 6th Ed. Eds Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U. McGraw Hill, New York 2001,1409-1434.
68. Black L, Selby R, Brnjac E, et al. *Bloody Easy Coagulation Simplified*, Second Edition. Ontario Regional Blood Coordinating Network. 2019.
69. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. *Am J Clin Pathol* 2006; 126: 133-139.
70. Lin Y, Callum JL. Emergency reversal of warfarin anticoagulation. *CMAJ* 2010; 182: 2004.

71. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012; 141(2 Suppl): e152S-e184S.
72. Compendium of Pharmaceuticals and Specialties. Vitamin K. Canadian Pharmacists Association, Ottawa 2001; 1860-1861.
73. Wilson SE, Douketis JD, Crowther MA. Treatment of warfarin-associated coagulopathy: A physician survey. *Chest* 2001; 120: 1972-1976.
74. Bolton-Maggs P, Brook L. The use of vitamin K for reversal of over-warfarinization in children. *Br J Haematol* 2002; 118: 924.
75. National Advisory Committee on Blood and Blood Products. 2020. Framework for appropriate use and distribution of solvent detergent treated plasma.
<https://nacblood.ca/en/resource/solvent-detergent-treated-plasma-sd-plasma>
76. Dichtelmuller DO, Biesert L, Fabrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. *Transfusion* 2009; 49: 1931-1943.
77. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. *J Thromb Thrombolysis* 2015; 39: 118-128.
78. Octaplasma Canadian Product Monograph, August 11, 2005. Octoplasma™ Solvent Detergent (S/D) Treated Plasma. https://pdf.hres.ca/dpd_pm/00055875.PDF Accessed 24/2/2022.
79. Schonewille H, Honohan A, van der Watering LM, et al. Incidence of alloantibody

formation after ABO-D or extended matched red blood cell transfusions: a randomized trial (MATCH) study. *Transfusion* 2016; 56: 311-320.

80. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and pre-storage WBC reduced platelets *Transfusion* 2002; 42: 556-566.
81. Garban F, Guyard A, Labussiere MD, et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. *JAMA Oncol* 2018; 4: 468-475.
82. Cohn CS, Stubbs J, Schwartz Y, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. *Transfusion* 2014; 54: 1927-1934.
83. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. *Anesthesiology* 2015; 122: 21-28.
84. Pinkerton PH, Coovadia AS, Goldstein J. Frequency of delayed hemolytic transfusion reactions following antibody screening and immediate-spin crossmatching. *Transfusion*. 1992; 32: 814-817.
85. Hong H, Xiao W, Lazarus HM, et al. Detection of septic transfusion reactions to platelet transfusion by active and passive surveillance. *Blood* 2016; 127: 496-502.
86. Storch EK, Rogerson B, Eder AF. Trend in ABO-incompatible RBC transfusion-related fatalities reported to the FDA, 2000-2019. *Transfusion*. 2020; 60: 2867-2875.
87. Canadian Blood Services. Surveillance Report 2020.
<https://professionaleducation.blood.ca/en/transfusion/publications/surveillance-report>
Accessioned 24/2/2022.

88. O'Brien SF, Yi Q-L, Goldman M, et al. Human T-cell lymphotropic virus: a simulation model to estimate risk with universal leukoreduction and testing strategies in Canada. *Vox Sang* 2018; 113: 750-759.
89. Serious Hazards of Transfusion Group (SHOT). <https://www.shotuk.org> Accessed 24/2/2022.
90. U.S. Food and Drug Administration. Vaccines, Blood and Biologics. <https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities> Accessed 24/2/2022.
91. Ontario Transfusion Transmitted Injuries Surveillance System (TTISS). Ontario TTISS Program Report. <https://ttiss.mcmaster.ca/> Accessed 24/2/2022.
92. Levy JH, Neal MD, Herman JH. Bacterial contamination of platelets for transfusion: strategies for prevention. *Crit Care*. 2018; 22: 271.
93. Palavecino EL, Yomtovian RA, Jacobs MR. Bacterial contamination of platelets. *Transfus Apher Sci* 2010; 42: 71-82.
94. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion- transmitted bacterial infection in the United States, 1998 through 2000. *Transfusion* 2001; 41: 1493- 1499.
95. Brecher ME, Hay SN. Bacterial contamination of blood components. *Clin Microbiol Rev* 2005; 18: 195-204.
96. Ramirez-Arcos S, Goldman M, Blajchman MA. Bacterial contamination. In *Transfusion Reactions*, 3rd Ed. Ed Popovsky, MA. Bethesda, MD: AABB Press, 2007; 163-206.
97. Blajchman, MA. Bacterial contamination and proliferation during the storage of cellular blood products. *Vox Sang* 1998; 74 (Suppl.2): 155-159.

98. U.S. Food & Drug Administration. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2009. <https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities>
99. Public Health Agency of Canada. Guideline for investigation of suspected transfusion transmitted bacterial contamination. Canada Communicable Disease Report 2008; 34S1: 1-8.
100. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev. 2008; 22: 1-34.
101. Storry JR, Clausen FB, Castilho L, et al. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology: Report of the Dubai, Copenhagen and Toronto meetings. Vox Sang. 2019; 114: 95-102.
102. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State: an analysis of 10-years experience. Transfusion 2000; 40: 1207-1213.
103. Nuttall GA, Abenstein JP, Stubbs JR, et al. Computerized bar code-based blood identification systems and near-miss transfusion episodes and transfusion errors. Mayo Clin Proc 2013; 88: 354-359.
104. Davenport RD. Hemolytic transfusion reactions. In Transfusion Reactions, 3rd Ed, Popovsky MA. AABB Press, Bethesda, MD, 2007; 1-55.
105. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6: 420-426.
106. Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007;

21: 1-12.

107. Mowla SJ, Kracalik IT, Sapiano MRP, et al. A comparison of transfusion-related adverse reactions among apheresis platelets, whole blood-derived platelets, and platelets subjected to pathogen reduction technology as reported to the National Healthcare Safety Network Hemovigilance Module. *Transfus Med Rev.* 2021; 35: 78-84.
108. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. *Transfusion* 2008; 48: 1061-1071.
109. Osselaer JC Cazenave JP, Lambermont M, et al. An active haemovigilance program characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. *Vox Sang* 2008; 94: 315-323.
110. Ning S, Solh Z, Arnold DM et al. Premedication for the prevention of nonhemolytic transfusion reactions: a systematic review and meta-analysis. *Transfusion.* 2019; 59: 3609-3616.
111. ISBT. Working Party on Haemovigilance. July 2011.
<https://www.isbtweb.org/asset/0FA5485B-5DCC-4E85-A3D61CE8DB17D504/>
Accessioned 24/2/2022.
112. Vlaar APJ, Toy P, Fung M, et al. A consensus redefinition of transfusion-related acute lung injury. *Transfusion.* 2019; 59: 2465-2476.
113. Peters AL, Van Stein D, Vlaar APJ. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. *Br J Haematol.* 2015; 170: 597-614.
114. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-

related acute lung injury. *Transfusion* 1985; 25: 573-577.

115. Middelburg RA, van Stein D, Briet E, et al. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systemic review. *Transfusion* 2008; 48: 2167-2176.
116. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. *Transfusion* 1997; 37: 719-726.
117. Kuldaneck SA, Kelher M, Silliman CC. Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update. *Expert Rev Hematol.* 2019; 12: 773-785.
118. Schmickl CN, Mastrobuoni S, Filippidis FT, et al. Male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury: a systematic review. *Crit Care Med.* 2015; 43: 205-225.
119. Popovsky MA, Haley NR. Further characterization of transfusion related acute lung injury: demographics, clinical and laboratory features and morbidity. *Immunohematology* 2000; 16: 157-159.
120. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. *Transfusion* 2004; 44: 1689-1694.
121. Engelfriet CP, Reesink HW, Brand A, et al. Transfusion related acute lung injury (TRALI). *International Forum. Vox Sang* 2001; 81: 269-283.
122. Perez-Alvarez I, Kopko PM. Transfusion-Associated Circulatory Overload. *Transfusion Reactions*, 5th Ed. AABB Press, Bethesda, MD, 2021; 331-345.
123. Alam A, Lin Y, Lima A, et al. The prevention of transfusion-associated circulatory overload.

Transfus Med Rev 2013; 27: 105-112.

124. ISBT. Working Party on Haemovigilance Transfusion-associated Circulatory Overload (TACO) Definition (2018). <https://www.isbtweb.org/resource/tacodefinition.html>
Accessioned 24/2/2022.
125. Bulle EB, Klanderman RB, Pendergrast J, et al. The recipe for TACO; a narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload. *Blood Rev* 2022; Mar 52:100891. doi 10.1016/j.blre.2021.100891. Epub 2021 Oct2.
126. Vamvakas E, Pineda AA. Allergic and Anaphylactic Reactions. In *Transfusion Reactions*, 2nd Ed. Ed Popovsky MA. AABB Press, Bethesda, MD, 2001; 83-128.
127. Palmer DS, O'Toole J, Montreuil T, et al. Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency. *Transfusion* 2010; 50 :1524-1531.
128. Sandler SG, Eder AF, Goldman M, et al. The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based. *Transfusion* 2015; 55: 199-204.
129. Koda Y, Watanabe Y, Soejima M, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoalbuminemic patients with antihaptoalbumin antibody that causes anaphylactic transfusion reactions. *Blood* 2000; 95; 1138-1143
130. Fontaine MJ, Jackson BP. Allergic and Anaphylactic Reactions. *Transfusion Reactions*, 5th Ed. AABB Press, Bethesda, MD, 2021; 81-105.
131. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. *Blood*. 2019; 133: 1831-1839.
132. Cardigan R, New HV, Tinegate H, et al. Washed red cells: theory and practice. *Vox Sang*

2020; 115: 606-616.

133. Fujihara H, Yamada C, Furumaki H, et al. Evaluation of the in hospital hemovigilance by introduction of the information technology-based system. *Transfusion* 2015; 55: 2898-2904.
134. Arnold DM, Hume HA. Hypotensive transfusion reactions. In *Transfusion Reactions*, 3rd Ed. Ed Popovsky MA. AABB Press, Bethesda, MD, 2007; 251-274.
135. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. Protocol v2.6. Atlanta, GA: Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 2021. <https://www.cdc.gov/nhsn/pdfs/biovigilance/bv-hv-protocol-current.pdf> Accessed 15/07/2022.
136. Py JY, Leo-Kodeli S, Fauveau L, et al. L'hypotension artérielle dans les effets indésirables receveurs: du signe clinique associé à la réaction transfusionnelle hypotensive. *Transfus Clin Biol.* 2009; 16: 12-20.
137. Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic transfusion reactions. *Transfusion* 1999; 39: 1097-1103.
138. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. *Blood Rev* 2001; 15: 69-83.
139. Powell Z, Jiang N, Shrestha R, et al. Would a National Antibody Register contribute to improving patient outcomes? *Blood Transfus.* 2022; 20: 132-142.
140. Luken JS, Folman CC, Lukens MV, et al. Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: A nation-wide policy change evaluation study in the Netherlands. *Transfusion.* 2021; 61: 713-721.

141. Liu C, Grossman BJ, Anderson KC. Transfusion-associated graft-vs-host disease. In Transfusion Reactions, 5th Ed. Ed. AABB Press, Bethesda, MD, 2021; 199-223.
142. Rühl H, Bein G, Sachs UJH. Transfusion-associated graft-vs-host disease. Transfus Med Rev 2009; 23: 62-71.
143. Schroeder ML. Transfusion-Associated Graft-versus- Host Disease. Br J Haematol 2002; 117: 275-287.
144. Kopolovic I, Ostro J, Tsubola H, et al. A systematic review of transfusion-associated graft-versus host disease. Blood 2015; 126: 406-414.
145. Council of Europe: Guide to the preparation, use and quality assurance of blood components. 20th Ed. Council of Europe, Strasbourg, France, 2020.
https://freepub.edqm.eu/publications/AUTOPUB_48/detail Accessed 25/2/2022
146. Serrano K, Chen D, Hansen AL, et al. The effect of timing of gamma-irradiation on hemolysis and potassium release in leukoreduced red cell concentrates stored in SAGM. Vox Sang 2014; 108: 379-381,
147. Foukaneli T, Kerr P, Bolton-Maggs PHB, et al; BCSH Committee. Guidelines on the use of irradiated blood components. Br J Haematol. 2020; 191: 704-724. .
148. McFarland JG. Posttransfusion purpura. In Transfusion Reactions, 3rd Ed. Ed Popovsky MA. AABB Press, Bethesda, MD, 2007; 275-299
149. Hawkins J, Aster RH, Curtis BR. Post-Transfusion Purpura: Current Perspectives. J Blood Med. 2019; 10: 405-415.
150. Menis M, Forshee RA, Anderson SA, et al. Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare

databases during 2011 through 2012. *Transfusion* 2015; 55: 284-295.

151. Pavenski K, Webert KE, Goldman M. Consequences of transfusion of platelet antibody: a case report and literature review. *Transfusion* 2008; 48: 1981-1989.
152. Wallis JP, Haynes S, Stark G, et al. Transfusion- related alloimmune neutropenia: an undescribed complication of blood transfusion. *Lancet* 2002; 360: 1073-1074.
153. O'Brien SF, Yi QL, Fan W, et al. Residual risk of HIV, HCV and HBV in Canada. *Transfus Apher Sci.* 2017; 56: 389-391.
154. O'Brien SF, Grégoire Y, Pillonel J, et al. HIV residual risk in Canada under a three-month deferral for men who have sex with men. *Vox Sang.* 2020; 115: 133-139.
155. Seed CR, Wong J, Polizzotto MN, et al. The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components. *Vox Sang* 2015; 109: 11-17.
156. Thiele T, Kruger W, Zimmermann K, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high- risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). *Transfusion* 2011; 51: 2620-2626.
157. National Advisory Committee on Blood and Blood Products. February 2017.
www.nacblood.ca/resources/guidelines/CMV.html Accessed 25/2/2022
158. Robitaille N, personal communication
159. O'Brien SF, Scalia V, Zuber E, et al. West Nile Virus in 2006 and 2007: the Canadian Blood Services' experience. *Transfusion* 2010; 50: 1118-1125.
160. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges

and remarkable progress. *Transfusion* 2010; 50: 2080- 2099.

161. Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for *Trypanosoma cruzi*. *Transfusion* 2010; 50: 2220-2232.
162. Ironside JW. Variant Creutzfeldt-Jacob disease. *Haemophilia* 2010; 16 (Suppl.5): 175-180.
163. Allain JP, Stramer SL, Carneiro-Proietti AB, et al. Transfusion-transmitted infectious disease. *Biologicals* 2009; 37: 71-77.
164. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. *Transfusion* 2009; 49(Suppl 2): 1S-29S.
165. Wagner SJ, Leiby DA, Roback JD. Existing and emerging blood-borne pathogens: impact on the safety of blood transfusion for the hematology/oncology patient. *Hematol Oncol Clin North Am.* 2019; 33: 739-748.
166. Moore FA, Moore EE, Sauaia A. Blood Transfusion. An independent risk factor for postinjury multiorgan failure. *Arch Surg* 1997; 132: 620-625.
167. Sihler KC, Napolitano LM. Complications of massive transfusion. *Chest* 2010; 137: 209-220.
168. Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. *J Trauma.* 2003; 54: 1127-1130.
169. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets and red blood cells in a 1:1:1 vs. a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA* 2015; 313: 471-482.
170. Diab YA, Wong ECC, Luban NLC. Massive transfusion in children and neonates. *Br J Haematol* 2013; 161: 15-26.

171. Chidester SJ, Williams N, Wang W, et al. A pediatric massive transfusion protocol. *J Trauma Acute Surg* 2012; 73: 1273-1277.
172. Alam A, Olarte R, Callum J, et al. Hypothermia indices among severely injured trauma patients undergoing urgent surgery: A single-centred retrospective quality review and analysis. *Injury*. 2018; 49: 117-123.
173. Rajagopalan S, Mascha E, Na J, et al. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. *Anesthesiology* 2008; 108: 71-77.
174. Perlman R, Callum J, Laflamme C, et al. A recommended early goal-directed management guideline for the prevention of hypothermia-related transfusion, morbidity, and mortality in severely injured trauma patients. *Crit Care*. 2016; 20: 107.
175. Giancarelli A, Birrer KL, Alban RF, et al. Hypocalcemia in trauma patients receiving massive transfusion. *J Surg Res*. 2016; 202: 182-187.
176. Vraets A, Lin Y, Callum JL. Transfusion-associated hyperkalemia. *Transfus Med Rev* 2011; 25: 184-196.
177. Sezdi M, Bayik M, Ulgen Y. Storage effects on the Cole-Cole parameters of erythrocyte suspensions. *Physiol Meas* 2006; 27: 623-635.
178. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. *Lancet*. 2020; 395: 1927-1936.
179. California Maternal Quality Care Collaborative. OB Hemorrhage Toolkit V 2.0. March 2015. www.cmqcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit Accessed

25/2/2022.

180. Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. *Ann Thorac Surg.* 2021; 112: 981-1004.
181. Karkouti K, McCluskey SA, Evans L, et al. Rationalizing blood conservation by using a patient- specific risk index. *Can J Anesth* 2002; 49: 72A.
182. Shah A, Palmer AJR, Klein AA. Strategies to minimize intraoperative blood loss during major surgery. *Br J Surg* 2020; 107: e26-e38.
183. Thrombosis Canada. Perioperative management of Antiplatelet Therapy. 2019.
https://thrombosiscanada.ca/wp-uploads/uploads/2022/02/36.-Perioperative-Management-of-Antiplatelet-Therapy_04July2021_minor-update-09Feb2022.pdf Accessed 25/2/2022.
184. Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. *NEJM* 2014; 370: 1494-1503.
185. Thrombosis Canada. DOACs - Perioperative management. 2021.
https://thrombosiscanada.ca/wp-uploads/uploads/2021/08/22.-NOACs-DOACs-Perioperative-Management_07August2021-1.pdf Accessed 25/2/2022.
186. Sheth KR, Bernthal NM, Ho HS, et al. Perioperative bleeding and non-steroidal anti-inflammatory disease: an evidence -based literature review and current clinical appraisal. *Medicine (Balt.)* 2020; 99: e20042.
187. Acute kidney injury: prevention, detection and management. 2019 NICE guideline [NG148] 18 dec 2019. <https://www.nice.org.uk/guidance/ng148> Accessed 25/2/2022.
188. Fowler RA, Berenson M. Blood conservation in the intensive care unit. *Crit Care Med* 2003; 31 (12 Suppl): S715-S720.

189. Thrombosis Canada. Warfarin – Perioperative management. 2021.
https://thrombosiscanada.ca/wp-uploads/uploads/2021/09/14.-Warfarin-Perioperative_14Sept2021.pdf Accessed 25/2/2022.
190. Clevenger B, Mallett SV, Klein AA, et al. Patient blood management to reduce surgical risk. *Br J Surg* 2015; 102: 1325-1337.
191. Elhenawy AM, Mayer SR, Bogshaw SM, et al. Role of preoperative intravenous iron therapy to correct anemia before major surgery: a systematic review and meta-analysis. *Syst Rev*. 2021; 10: 36.
192. Shin HW, Park JJ, Kim HJ, et al. Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis. *PLoS One*. 2019; 14: e0215427.
193. Perelman I, Winter R, Sikora L, et al. The efficacy of postoperative iron therapy in improving clinical and patient-centered outcomes following surgery: a systematic review and meta-analysis. *Transfus Med Rev*. 2018; 32: 89-101.
194. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice daily doses in iron depleted young women. *Blood* 2015; 126: 1981- 1989.
195. Tolkein Z, Stecher L, Mander LP, et al. Ferrous sulphate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS One* 2015; 10: e0117383.
196. Bager P, Dahlerup JF. Randomized clinical trials: oral vs. intravenous iron after upper gastrointestinal tract haemorrhage - a placebo-controlled study. *Aliment Pharmacol Ther*

2014; 39: 176-187.

197. Barraclough KA, Brown F, Hawley CM, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. *Nephrol Dial Transplant*. 2012; 27: 4146-4153.
198. Powers JM, Buchanan GR, Adix L, et al. Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia: a randomized clinical trial. *JAMA* 2017; 317: 2297-2304.
199. Kim YH, Chung HH, Kang SB, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. *Acta Haematol* 2009; 121: 37-41.
200. Malinowski AK, Murji A. Iron deficiency and iron deficiency anemia in pregnancy. *CMAJ* 2021; 193: E1137-1138.
201. Blumenstein I, Shanbhag S, Langguth P, et al. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety. *Expert Opin Drug Saf*. 2021; 20: 757-769.
202. Nitescu N, Bengtsson A, Bengtson JP. Blood salvage with continuous autotransfusion system compared with a haemofiltration system. *Perfusion* 2002; 17: 357-362.
203. Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. *Cochrane Database of Systematic Reviews* 2010. Issue 4. Art. No.: CD001888. doi: 10.1002/14651858.CD001888.pub4.
204. Wang G, Bainbridge D, Martin J, et al. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. *Anesth Analg* 2009; 109: 320-330.

205. Klein AA, Bailey CR, Charlton AJ, et al. Association of Anaesthetists guidelines: cell salvage for peri-operative blood conservation 2018. *Anaesthesia* 2018 ;73: 1141-1150.
206. Khan KS, Moore PAS, Wilson MJ, et al. Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO). *PLoS Med.* 2017; 14: e1002471.
207. Cho BC, Serini J, Zorrilla-Vaca A, et al. Impact of preoperative erythropoietin on allogeneic blood transfusions in surgical patients: results from a systematic review and meta-analysis. *Anesth Analg.* 2019; 128: 981-992.
208. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplement to prevent allogeneic blood transfusion in total hip joint arthroplasty. *Ann Intern Med* 2000; 133: 845-854.
209. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoietin alfa in patients undergoing major orthopedic surgery. *Am J Orthop* 1996; 25: 544-552.
210. Karkouti K, McCluskey SA, Evans L, et al. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. *Can J Anesth* 2005; 52: 362-368.
211. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high risk cardiac surgery. *NEJM* 2008; 358: 2319-2331.
212. Henry DA, Carless PA, Moxey AJ, et al. Anti- fibrinolytic use for minimising perioperative allogeneic blood transfusion. *Cochrane Database of Systematic Reviews.* 2011; 3: CD001886.
213. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood

conservation in cardiac surgery: the Society of Thoracic Surgery and Cardiovascular Anesthetists Clinical Practice Guidelines. *Ann Thorac Surg* 2007; 83 (5 Suppl): S27-S86.

214. Myles PS, Smith JA, Forbes A, et al. Tranexamic acid in patients undergoing coronary-artery surgery *NEJM* 2017; 376: 136-148
215. Shi J, Zhou C, Pan W, et al. Effect of high- vs low-dose tranexamic acid infusion on need for red blood cell transfusion and adverse events in patients undergoing cardiac surgery: The OPTIMAL Randomized Clinical Trial. *JAMA*. 2022; 328: 336-347.
216. Houston BL, Uminski K, Mutter T, et al. Efficacy and safety of tranexamic acid in major non-cardiac surgeries at high risk for transfusion: a systematic review and meta-analysis. *Transfus Med Rev*. 2020; 34: 51-62.
217. Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic acid in patients undergoing noncardiac surgery. *NEJM* 2022; 386: 1986-1997.
218. Shemshaki H, Nourian SM, Nourian N, et al. One step closer to sparing total blood loss and transfusion rate in total knee arthroplasty: a meta- analysis of different methods of tranexamic acid administration. *Arch Orthop Trauma Surg* 2015; 135: 573-588.
219. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. *Lancet* 2010; 376: 23-32
220. Guyette FX, Brown JB, Zenati MS, et al. Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: A double-blind, placebo-controlled, randomized clinical trial. *JAMA Surg* 2020; 156: 11–20.
221. Rowell SE, Meier EN, McKnight B, et al. Effect of out-of-hospital tranexamic acid vs

placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury. *JAMA* 2020; 324: 961-974. Erratum in: *JAMA* 2020; 324: 1683.

222. Memtsoudis SG, Cozowicz C, Bekeris J, et al. Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analysis of current literature. *Reg Anesth Pain Med.* 2021; 46: 971-985.
223. Richman JM, Rowlingson AJ, Maine DN, et al. Does neuraxial anesthesia reduce intraoperative blood loss? A meta-analysis. *J Clin Anesth.* 2006; 18: 427-435.
224. Menkis AH, Martin J, Cheng DCH. Drugs, devices, technologies and techniques for blood management in minimally invasive and conventional cardiothoracic surgery. *Innovations* 2012; 7: 229-241.
225. Daud A, Kaur B, McClure GR, Belley-Cote EP, et al. Fibrin and thrombin sealants in vascular and cardiac surgery: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg.* 2020; 60: 469-478.
226. Wells CI, Ratnayake CBB, Mentor K, et al. Haemostatic efficacy of topical agents during liver resection: a network meta-analysis of randomised trials. *World J Surg.* 2020; 44: 3461-3469.
227. Haensig M, Kempfert J, Kempfert PM, et al. Thrombelastometry guided blood-component therapy after cardiac surgery: a randomized study. *BMC Anesthesiol.* 2019; 19: 201.
228. Bonnet A, Gilquin N, Steer N, et al. The use of a thromboelastometry-based algorithm reduces the need for blood product transfusion during orthotopic liver transplantation: a

- randomised controlled study. *Eur J Anaesthesiol.* 2019; 36: 825-833.
229. Karkouti K, Callum J, Wijeyesundera DN, et al. Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered Randomized controlled trial. *Circulation.* 2016; 134: 1152-1162.
230. Alayash A. Blood substitutes; why haven't we been more successful. *Trends Biotechnol* 2014; 32: 177-185.
231. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. *Cochrane Database Syst Rev* 2012; 14 Mar. doi: 10.1002/14651858.CD005011.pub4.
232. Barile L, Fominskiy E, Di Tomasso N, et al. Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis of randomized trials. *Anesth Analg.* 2017; 124: 743-752.
233. Janssen-Ortho Inc. Product monograph. EPREX® sterile solution. August 16, 2021. https://pdf.hres.ca/dpd_pm/00041771.PDF Accessed 25/2/2022.
234. Cody JD, Hodson EM. Recombinant human erthropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. *Cochrane Database Syst Rev* 2016; 1: CD003266. doi: 10.1002/14651858.CD003266.pub3
235. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *NEJM* 2009; 361: 2019-2032.
236. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *NEJM* 2006; 355: 2085-2098.
237. Vifor Fresenius Medical Care Renal Pharma <http://www.treatalgo.com/kdigo-anemia/dia->

[esa.html](#)

238. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179: 1154-1162.
239. Kidney International Official Journal of the International Society of Nephrology. Kidney International Supplements. 2012; 2 (4) August (2) 2012. <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf> Accessed 25/2/2022.
240. Bohlius J, Tonia T, Schwarzer G. Twist and Shout: One decade of meta-analyses of erythropoiesis- stimulating agents in cancer patients. Acta Haematol 2011; 125: 55-67.
241. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996- 5010.
242. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407. doi: 0.1002/14651858.CD003407.pub5.
243. Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016 Feb 4; 2 (2):CD009624. doi: 10.1002/14651858.CD009624.pub2.
244. Margaron MP, Soni N. Serum albumin: touchstone or totem? Anesthesia 1998; 53: 789-803.
245. Boldt J. The good, the bad and the ugly: should we completely banish human albumin from our intensive care units. Anesth Analg 2000; 91: 887- 895.

246. Plasbumin®-25 package insert. Grifols, Revised June 2018.
247. China L, Freemantle N, Forrest E, et al. A randomized trial of albumin Infusions in hospitalized patients with cirrhosis. *NEJM* 2021; 384: 808-817.
248. Howard G, Downward G, Bowie D. Human serum albumin induced hypotension in the post-operative phase of cardiac surgery. *Anaesth Intensive Care* 2001; 29: 591-594.
249. Simonetti RG, Perricone G, Nikolova D, et al. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. *Cochrane Database Syst Rev.* 2019; 6:CD004039. doi: 10.1002/14651858.CD004039.pub2.
250. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; 74: 1014-1048.
251. Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis – induced circulatory dysfunction in cirrhotics: a randomized pilot study. *Am J Gastroenterol* 2008; 103: 1399-1405.
252. Lata J, Marecek Z, Fejfar T, et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites – a randomized multicentric study. *Hepatogastroenterology* 2007; 54: 1930-1933.
253. Bari K, Minano C, Shea M, et al. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. *Clin Gastroenterol Hepatol* 2012; 10: 1169-1175.
254. Matsusaki M, Aridome K, Emoto S, et al. Clinical practice guideline for the treatment of

malignant ascites; section summary in Clinical Practice Guideline for peritoneal dissemination (2021). *Int J Clin Oncol* 2022; 27: 1–6.

255. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *NEJM* 1999; 341: 403-409.
256. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. *NEJM*; 384: 818-828.
257. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology* 1999; 29: 1690-1697.
258. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome; a randomized trial. *Hepatology* 2015; 62: 567-574.
259. Martin-Llahi M, Pepin MN, Guerara M, et al. Terlipressin and albumin vs. albumin in patients with cirrhosis and hepatorenal syndrome. *Gastroenterology* 2008; 134: 1352-1359.
260. Martin GS, Bassett P. Crystalloids vs. colloids for fluid resuscitation in the Intensive Care Unit: A systematic review and meta-analysis. *J Crit Care*. 2019; 50: 144-154.
261. Patel A, Laffan MA, Waheed U, et al. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. *BMJ*. 2014; 349: g4561.
262. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic reviews of randomized controlled trials. *BMJ* 1998; 317: 235-240.
263. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-

- analysis of randomized controlled trials. *Ann Intern Med* 2001; 135: 149-164.
264. Navickis, RJ, Greenhalgh, DG, Wilkes, MM. Albumin in burn shock resuscitation: a meta-analysis of controlled clinical studies. *J Burn Care Res* 2016; 37: e268–e278.
265. Greenhalgh DG. Burn resuscitation: the results of the ISBI/ABA survey. *Burns* 2010; 36: 176-182.
266. Pham TN, Cancio LC, Gibran NS. American Burn Association Practice Guidelines, burn shock resuscitation. *J Burn Care Res* 2008; 29: 257-266.
267. Silver GM, Klein MB, Herndon DN, et al. Standard operating procedures for the clinical management of patients enrolled in a prospective study of inflammation and the host response to thermal injury. *J Burn Care Res* 2007; 28: 222-230.
268. Knoll GA, Grabowski JA, Dervin GF, et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. *J Am Soc Nephrol.* 2004; 15: 487-492.
269. Rostoker G, Griuncelli M, Loridon C, et al. A pilot study of routine colloid infusion in hypotension-prone dialysis patients unresponsive to preventive measures. *J Nephrol.* 2011; 24: 208-217.
270. van der Sande FM, Kooman JP, Barendregt JN, et al. Effect of intravenous saline, albumin, or hydroxyethylstarch on blood volume during combined ultrafiltration and hemodialysis. *J Am Soc Nephrol.* 1999; 10: 1303-1308.
271. Macedo E, Karl B, Lee E, et al. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients. *Crit Care.* 2021; 25: 18.
272. Lee EH, Kim WJ, Kim JY, et al. Effect of exogenous albumin on the incidence of

postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl. *Anesthesiology*. 2016; 124: 1001-1011.

273. Uhlig C, Silva PL, Deckert S, et al. Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care*. 2014; 18: R10.
274. Pesonen E, Vlasov H, Suojaranta R, et al. Effect of 4% albumin solution vs. Ringer acetate on major adverse events in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized clinical trial. *JAMA* 2022; 328: 251-258.
275. Canadian Blood Services. Annual Report 2020-2021.
https://www.blood.ca/sites/default/files/CBS_AR_2021_EN_FINAL.pdf?utm_source=direct&utm_medium=blood&utm_campaign=AR2021 Accessed 25/2/2022.
276. Statista. Immunoglobulin consumption in select countries. 2017.
www.statista.com/statistics/1055466/immunoglobulin-consumption-in-select-countries/
Accessioned 25/2/2022.
277. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. *Vox Sang* 2000; 78: 86-95.
278. Ontario Regional Blood Coordinating Network. Immune Globulin Toolkit for Ontario. 2018
<https://transfusionontario.org/wp-content/uploads/2020/06/Immune-globulin-toolkit-for-ontario-v3.0-1.pdf> Accessed 25/2/2022.
279. Kleinman S. Adverse reactions to IVIG. In *IVIG Utilization Management Handbook* 1st

Ed. BC Provincial Blood Coordinating Office 2002; 7-10.

280. Stiehm ER. Adverse effects of human immunoglobulin therapy. *Transfus Med Rev* 2013; 27: 171-178.
281. Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. *Autoimmun Rev.* 2016; 15: 71-81.
282. Souayah N, Hasan A, Khan HM, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. *J Clin Neuromuscul Dis.* 2011; 12 (Suppl 4): S1-S10.
283. Bharath V, Eckert K, Kang M, et al. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis; a retrospective review at a single tertiary care centre. *Transfusion* 2015; 55: 2597-2605
284. Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. *Ann Pharmacother.* 2015; 49: 715-726.
285. Pendergrast J, Armali C, Callum J, et al. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. *Transfusion* 2021; 61: 1053-1063.
286. Ammann EM, Jones MP, Link BK, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. *Blood* 2016; 127: 200-207.
287. Niebanck AE, Kwiatkowski JL, Raffini LJ. Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. *J Pediatr Hematol Oncol.*

2005; 27: 145-147.

288. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. *JAMA* 1996; 276: 1563-1567.
289. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement therapy. *J Allergy Clin Immunol* 2013; 131: 1699- 1701.
290. BC Provincial Blood Coordinating Office, Provincial Health Authority. Intravenous Immunoglobulin (IVIG) Utilization Management Program Recommendations. 2019. https://www.pbco.ca/images/Programs/IVIG_Provincial_Program/UMIVIG0007_IVIG_Utilization_Management_Program_Guidelines_V42.pdf Accessed 25/2/2022.
291. United Kingdom Clinical Guidelines for Immunoglobulin Use. 2nd Ed. 2011. United Kingdom Department of Health. www.gov.uk/government/publications/clinical-guidelines-for-immunoglobulin-use-second-edition-update Accessed 25/2/2022.
292. Shehata N, Palda V, Brown N, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence based practice guideline. *Transfus Med Rev* 2010; 24 (Suppl.1): S28-S50
293. Agostini C, Blau I-W, Kimby E, et al. Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion. *Exp Rev Clin Immunol* 2016; 12: 921-926.
294. Castagnoli R, Delmonte OM, Calzoni E, et al. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. *Front Pediatr* 2019; 7: 295.
295. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric

- antigen receptor T cells for B-cell malignancies. *Blood* 2020; 136: 925–935.
296. Shehata N, Falda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence based practice guideline. *Transfus Med Rev* 2010; 24 (Suppl.1): S7-S27.
297. Peraldi M, Akposso K, Hayman J, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. *Transplantation* 1996; 62: 1670-1673.
298. Casadei DH, del C. Rial M del C, Opelz G, et al. Randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. *Transplantation* 2001; 71: 53-58.
299. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NH IGo2 Trial. *J Am Soc Nephrol* 2004; 15: 3256-3262.
300. Roberts D, Jiang S, Chadban S. The treatment of acute antibody-mediated rejection in kidney transplant recipients – a systematic review. *Transplantation* 2012; 94: 775-783.
301. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev* 2007; 21 (Suppl.1): S9-S56.
302. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv.* 2019; 3: 3829-3866. Erratum: *Blood Adv* 2020; 4: 252.
303. Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal

- alloimmune thrombocytopenia. *Am J Obstet Gynecol.* 2021; 225: 120-127.
304. Lakkaraja M, Jin JC, Manotas KC, et al. Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. *Transfusion.* 2016; 56: 2449-2454.
305. Hillis CM, Schimmer AD, Couban S, et al. The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. *Ann Hematol* 2005; 94: 541–545.
306. Zwiers C, Scheffer-Rath ME, Lopriore E, et al. Immunoglobulin for alloimmune hemolytic disease in neonates. *Cochrane Database Syst Rev.* 2018; 3(3):CD003313. doi: 10.1002/14651858.CD003313.pub2.
307. American Academy of Pediatrics Clinical Practice Guideline. Management of hyperbilirubinemia in a newborn infant 35 or more weeks of gestation. *Pediatrics* 2004; 114: 297-316.
308. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem- cell transplantation? A randomized, double-blind, placebo-controlled, multicenter trial. *Ann Intern Med* 2003; 139: 8-18.
309. Saad A, de Lima M, Anand S, et al. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2020; 18: 599-634.
310. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurological conditions. *Transfus Med Rev* 2007; 21 (Suppl.1): S57-S107.
311. Kuitwaard K, de Gelder J, Tio-Gillen A, et al. Pharmacokinetics of intravenous

- immunoglobulin and outcome in Guillain-Barre syndrome. *Ann Neurol* 2009; 66: 597-603.
312. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. *Lancet Neurol* 2008; 7: 136-144.
313. Merkies I Bril V, Dalakas M, et al. Health-related quality-of-life improvements in CIPD with immune globulin IV 10%: The ICE Study. *Neurology* 2009; 72: 1337-1344.
314. Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. *Cochrane Database Syst Rev*. 2017; 1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2.
315. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. *J Peripher Nerv Syst*. 2021; 26: 242-268.
316. Hartung HP, Mallick R, Bril V, et al. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. *Eur J Neurol*. 2020; 27: 196-203.
317. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. *J Peripher Nerv Syst*. 2010; 15: 295-301.

318. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016; 87: 419-425.
319. Alipour-Faz A, Shojaei M, Peyvandi H, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. *Acta Neurol Belg*. 2017; 117: 245-249.
320. Gadian J, Kirk E, Holliday K, et al. Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. *Dev Med Child Neurol*. 2017; 59: 136-144.
321. Abboud H, Probasco JC, Irani S, et al; Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. *J Neurol Neurosurg Psychiatry*. 2021; 92: 757-768.
322. Ortiz JF, Ghani MR, Morillo Cox Á, et al. Stiff-Person Syndrome: A Treatment Update and New Directions. *Cureus*. 2020; 12: e11995.
323. Titulaer M, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with antiNMDA receptor encephalitis: an observational cohort study. *Lancet Neurol* 2013; 12: 157-165.
324. Kampylafka E, Kosmidis ML, Panagrotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: A 4-year follow-up study. *Clin Exp Rheumatol* 2012; 30: 397-401.
325. Callander J, Robson Y, Ingram J, et al. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. *Br J Dermatol*. 2018; 179: 1248-1255.
326. Bascić-Kes V, Kes P, Zavoreo I, et al. Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases. *Acta Clin Croat*. 2012; 51: 673-

683.

327. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019; 78: 736-745.
328. Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 Guideline on diagnosis and management of cardiovascular sequelae in Kawasaki Disease. *Circ J*. 2020; 84: 1348-1407.
329. Barron SJ, DelVecchio MT, Aronoff C. Intravenous immunoglobulin in the treatment of Stevens- Johnson syndrome and toxic epidermal necrolysis: a meta-analysis and meta-regression of observational studies. *Inter J Dermatol* 2015; 54: 108-115.
330. McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. *Br J Dermatol*. 2019; 181: 37-54.
331. Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. *Br J Dermatol*. 2016; 174: 1194-1227.
332. Enk A, Hadaschik E, Eming R, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. *J Dtsch Dermatol Ges*. 2017; 15: 228-241.
333. Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. *J Am Acad Dermatol*. 2020; 82: 575-585.e1.
334. Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. *J Cutan Med Surg*. 2006; 10: 205-221.

335. Schmidt E, Rashid H, Marzano AV, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. *J Eur Acad Dermatol Venereol*. 2021; 35: 1926-1948.
336. Stephenson MD. Topics in obstetrics and gynecology. In *IVIG Utilization Management Handbook 1st Ed*. BC Provincial Blood Coordinating Office, April 2002, 81-89.
337. Cáliz Cáliz R, Díaz Del Campo Fontecha P, Galindo Izquierdo M, et al. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations. *Reumatol Clin (Engl Ed)*. 2020; 16: 133-148.
338. Committee on Practice Bulletins—Obstetrics, American College of Obstetricians and Gynecologists. Practice Bulletin No. 132: Antiphospholipid syndrome. *Obstet Gynecol*. 2012; 120: 1514-1521.
339. Daya S, Gunby J, Porter F, et al. Critical analysis of intravenous immunoglobulin therapy for recurrent miscarriage. *Hum Reprod Update* 1999; 5: 475-482.
340. Stephenson MD, Fluker MR. Treatment of repeated unexplained in vitro fertilization failure with intravenous immunoglobulin: a randomized placebo-controlled Canadian trial. *Fertil Steril* 2000; 74: 1108-1113.
341. Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. *Curr Opin Crit Care* 2001; 7: 354-361.
342. Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. *Cochrane Data Base Syst Rev*, 2013 (9); CD001090.

doi: 10.1002/14651858.CD001090.pub2.

343. Kaul R, McGeer A, Norby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal septic shock syndrome – a comparative observational study. *Clin Infect Dis* 1999; 28: 800-807.
344. Darenberg J, Ihendyana N, Sjolín J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2003; 37: 333-340.
345. Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Pediatr Crit Care Med*. 2020; 21: 186-195.
346. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med*. 2017; 43: 304-377.
347. Centers for Disease Control and Prevention. Streptococcal Toxic Shock Syndrome. www.cdc.gov/groupastrep/diseases-hcp/Streptococcal-Toxic-Shock-Syndrome.html
Accessioned 25/2/2022.
348. Parks T, Wilson C, Curtis N, et al. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. *Clin Infect Dis*. 2018; 67: 1434-1436.
349. Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. *Infect Dis Clin North Am*. 2017; 31: 497-511.
350. Sigel J. Immunoglobulins and Obesity. *Pharmacy Practice News* 2010; 37: 1.

351. National Advisory Committee on Blood and Blood Products. Recommendations for use of Prothrombin Complex Concentrates in Canada 2014.
www.nacblood.ca/resources/guidelines/PCC-recommendations-final-2014-05-16.pdf
Accessioned 25/2/2022.
352. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. *Int J Clin Pract* 2008; 62: 1614-1622.
353. Sarode R, Milling TJ, Rejaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized plasma-controlled phase IIIb study. *Circulation* 2013; 128: 1234-1243.
354. Piran S, Khatib R, Schulman S, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. *Blood Adv.* 2019; 3: 158-167.
355. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizimab for Dabigatran reversal. *NEJM* 2015; 373: 511-520.
356. Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: The FIBRES Randomized Clinical Trial. *JAMA* 2019; 322: 1966-1976.
357. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. *Crit Care* 2019; 23: 98.
358. Stein E, McMahon B, Kwaan H, et al. The coagulopathy of APL revisited. *Best Pract Res Clin Hematol* 2009; 22: 153-163.
359. Canadian Blood Services. Plasma protein and related products – Customer Table of

Information (2022). https://www.blood.ca/sites/default/files/F802238_2022-02-09.pdf
Accessioned 25/2/2022.

360. Qureshi, H, Massey E, Kirwan D, et al. BCSH guidelines for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. *Transfus Med* 2014; 24: 8-20.
361. Visser GHA, Thommesen T, Di Renzo GC, et al. FIGO/ICM guidelines for preventing Rhesus disease: A call to action. *Int J Gynaecol Obstet*. 2021; 152: 144-147.
362. Weinstein R, Simard A, Ferschke J, et al. Prospective surveillance of D- recipients of D+ apheresis platelets: alloimmunization against D is not detected. *Transfusion* 2015; 55: 1327-1330.
363. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv*. 2020; 4: 327-355.
364. National Institutes of Health. *The Management of Sickle Cell Disease*, 4th Ed. revised June 2002. NIH National Heart, Lung and Blood Institute. NIH Publication No. 02-2117. https://www.nhlbi.nih.gov/files/docs/guidelines/sc_mngt.pdf Accessed 25/2/2022.
365. Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. *Transfusion*. 2010; 50: 13-19.
366. Moulds JM, Hayes S, Wells TD. DNA analysis of Duffy genes in American blacks. *Vox Sang*. 1998; 74: 248-252
367. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. *Semin Hematol* 2001; 38: 14-22.

368. Pecker LH, Schaefer BA, Luchtman-Jones L. Knowledge insufficient: the management of haemoglobin SC disease. *Br J Haematol*. 2017 Feb; 176: 515-526.
369. Swerdlow PS. Red cell exchange in sickle cell disease. *Hematology Am Soc Hematol Educ Program* 2006: 48-53.
370. Yawn BP, Buchanan G, Afeniyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence based report by expert panel members. *JAMA* 2014; 312: 1033-1048.
371. Josephson CD, Su LL, Hillyer KL, et al. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. *Transfus Med Rev* 2007; 21: 118-133.
372. Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. *Blood* 1986; 67: 1411-1417.
373. Owusu-Ofori S, Remington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. *Cochrane Database Syst rev* 2017; Nov 7 11 (11): CD003425. doi: 10.1002/14651858.CD003425.pub4.
374. Evidence-Based Management of Sickle Cell Disease Expert Panel Report, 2014 NHLBI. www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
Accessioned 25/2/2022.
375. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. *NEJM* 1995; 333: 206-213.

376. Steinberg MH. Management of sickle cell disease. *NEJM* 1999; 340: 1021-1028.
377. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography *NEJM* 1998; 339: 5-11.
378. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia- TCD With transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. *Lancet*. 2016; 387: 661-670.
379. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH) *Blood* 2012; 119: 3925-3932.
380. DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. *NEJM* 2014 Aug 21; 371: 699-710.
381. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. *J Pediatr* 2001; 139: 785-789.
382. Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. *NEJM* 1988; 319: 1447-1452.
383. Wanko SO, Telen MJ. Transfusion management in sickle cell disease. *Hematol Oncol Clin North Am* 2005; 19: 803-826, v-vi.
384. Walker EM, Mitchum EN, Rous SN, et al. Automated erythrocytapheresis for relief of priapism in sickle cell hemoglobinopathies. *J Urol* 1983; 130: 912-916.
385. Mantadakis E, Ewalt DH, Cavender JD, et al. Outpatient penile aspiration and epinephrine

- irrigation for young patients with sickle cell anemia and prolonged priapism. *Blood* 2000; 95: 78-82.
386. Chernoff AI, Shapleigh JB, Moore CV. Therapy of chronic ulceration of the legs associated with sickle cell anemia. *JAMA* 1954; 155: 1487-1491.
387. Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. *Blood* 2015; 126: 2424-2435
388. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis- associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. *Blood* 2006; 107: 2279-2285.
389. Vichinsky EP, Luban NLC, Wright E, et al. Prospective RBC phenotype matching in a stroke- prevention trial in sickle cell anemia: a multicentre transfusion trial. *Transfusion* 2001; 41: 1086-1092
390. Win N, New H, Lee E, et al Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. *Transfusion* 2008; 48: 1231-1238.
391. Pirenne F, Yazdanbasche K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. *Blood* 2018; 131: 2773-1781.
392. Win N, Sinha S, Lee E et al. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. *Transfus Med Rev* 2010; 24: 64-67.
393. Alexy T, Pais E, Armstrong JK, et al. Rheologic behavior of sickle and normal red blood cell mixtures in sickle plasma: implications for transfusion therapy. *Transfusion* 2006; 46:

912-918.

394. Johnson CS. Arterial blood pressure and hyperviscosity in sickle cell disease. *Hematol Oncol Clin North Am* 2005; 19: 827-37.
395. Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society Clinical Practice Guideline: diagnosis, risk stratification, and management of pulmonary hypertension in sickle cell disease. *Am J Respir Crit Care Med* 2014; 189: 727-740.
396. Badawy SM, Liem RI, Rigsby CK, et al. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease. *Br J Haematol.* 2016; 175: 705-713
397. Canadian Blood Services. Product Costing 2021-2022.
398. Shander A, Hofmann A, Ozawa S, et al. Activity based costs of blood transfusions in surgical patients at four hospitals. *Transfusion* 2010; 50: 753-765.
399. Hofmann A, Ozawa S, Shander A. Activity-based cost of platelet transfusions in medical and surgical inpatients at a US hospital. *Vox Sang.* 2021; 116: 998-1004.
400. Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical patients at a US hospital. *Vox Sang* 2016; 111: 55-61.